Shopping Cart
- Remove All
- Your shopping cart is currently empty
LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $700 | 8-10 weeks | |
5 mg | $1,800 | 8-10 weeks |
Description | LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects. |
In vivo | In dog coronary stenosis, LCB 2853 demonstrates high efficacy with an ED50 of 7.2 μg/kg. In rat venous thrombosis induced by venous injury and blood stasis, perfused LCB 2853 reduces thrombus weight in a dose-dependent manner with an ED50 of 220 μg/kg/min[1]. In vivo, LCB 2853 shows an ED50 below 1 mg/kg i.v. against platelet aggregation and vasoconstriction, observed in rat arachidonic acid (AA)-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) and in AA-induced sudden death in mice (ED50 = 0.44 mg/kg). Additionally, LCB 2853 effectively blocks U 46619-induced bronchoconstriction after i.v. administration (ED50 = 18.4 μg/kg)[2]. |
Molecular Weight | 421.94 |
Formula | C21H24ClNO4S |
Cas No. | 141335-10-6 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.